Dexamethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 3, 2004, Pages 1108-1116

  Scholz, I V ^a   Cengic, N ^a   Goke B ^a   Morris, J C ^b   Spitzweg, C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; BICALUTAMIDE; DEXAMETHASONE; IODINE 131; MESSENGER RNA; MIBOLERONE; RADIOACTIVE IODINE; RECEPTOR BLOCKING AGENT; SODIUM IODIDE SYMPORTER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INCUBATION TIME; MALE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 1642399824     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030926     Document Type: Article

References (49)

1. Parker SL, Tong T, Bolden S, Wingo PA 1997 Cancer statistics, 1997. CA Cancer J Clin 47:5-27
2. Stearns ME, McGarvey T 1992 Prostate cancer: therapeutic, diagnostic, and basic studies. Lab Invest 67:540-552
3. Harrington KJ, Spitzweg C, Bateman AR, Morris JC, Vile RG 2001 Gene therapy for prostate cancer: current status and future prospects. J Urol 166: 1220-1233
4. Mazzaferri EL 1996 Carcinoma of follicular epithelium: radiodine and other treatments and outcomes. In: Braverman LE, Utiger RD, eds. The thyroid: a fundamental and clinical text. Philadelphia: Lippincott-Raven; 922-945
5. Dai G, Levy O, Carrasco N 1996 Cloning and characterization of the thyroid iodide transporter. Nature 379:458-460
6. Spitzweg C, Morris JC 2002 The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf) 57:559-574
7. Hart IR 1996 Tissue specific promoters in targeting systemically delivered gene therapy. Semin Oncol 23:154-158
8. Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY, Morris JC 1999 Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 59:2136-2141
9. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC 2000 Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 60:6526-6530
10. Fakah M, Johnson CS, Trump DL 2002 Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 60:553-561
11. Weiss SJ, Philipp NJ, Grollmann EF 1984 Iodine transport in a continuous line of cultured cells from rat thyroid. Endocrinology 114:1090-1098
12. Kaminsky SM, Levy O, Salvador C, Dai G, Carrasco N 1994 Na-I symporter activity is present in membrane vesicles from thyrotropin-deprived non-I-transporting cultured thyroid cells. Proc Natl Acad Sci USA 91:3789-3793
13. Castro MR, Bergert ER, Beito TG, Roche PC, Ziesmer SC, Jhiang SM, Goellner JR, Morris JC 1999 Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer. J Endocrinol 163:495-504
14. Cho JY, Shen DH, Yang W, Williams B, Buckwalter TL, La Perle KM, Hinkle G, Pozderac R, Kloos R, Nagaraja HN, Barth RF, Jhiang SM 2002 In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Ther 9:1139-1145
15. Min JJ, Chung JK, Lee YJ, Shin JH, Yeo JS, Jeong JM, Lee DS, Bom HS, Lee MC 2002 In vitro and in vivo characteristics of a human colon cancer cell line, SNU-C5N, expressing sodium-iodide symporter. Nucl Med Biol 29:537-545
16. Haberkorn U, Henze M, Altmann A, Jiang S, Morr I, Mahmut M, Peschke P, Kübler W, Debus J, Eisenhut M 2001 Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 42:317-325
17. Mandell RB, Mandell LZ, Link CJ 1999 Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 59:661-668
18. Nakamoto Y, Saga T, Misaki T, Kobayashi H, Sato N, Ishimori T, Kosugi S, Sakahara H, Konishi J 2000 Establishment and characterization of a breast cancer cell line expressing Na+/I-symporters for radioiodide concentrator gene therapy. J Nucl Med 41:1898-1904
19. Smit JWA, Schröder-van der Elst JP, Karperien M, Que I, van der Pluijm G, Goslings B, Romijn JA, van der Heide D 2000 Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid 10: 939-943
20. - symporter gene. Endocrinology 138:4493-4496
21. Boland A, Ricard M, Opolon P, Bidart J-M, Yeh P, Filetti S, Schlumberger M, Perricaudet M 2000 Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 60:3484-3492
22. Smit JW, Schroder-Van der Elst JP, Karperien M, Que I, Stokkel M, van der Heide D, Romijn JA 2002 Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab 87:1247-1253
23. Carlin S, Cunningham SH, Boyd M, McCluskey AG, Mairs RJ 2000 Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two-and three-dimensional models. Cancer Gene Ther 7:1529-1536
24. La Perle KMD, Shen D, Buckwalter TLF, Williams B, Haynam A, Hinkle G, Pozderac R, Capen CC, Jhiang SM 2001 In vivo expression and function of the sodium iodide symporter following gene transfer in the MATLyLu rat model of metastatic prostate cancer. Prostate 50:170-178
25. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL 1995 Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76:96-100
26. Weitzman A, Shelton G, Zuech N, Owen CE, Judge T, Benson M, Sawczuk I, Katz A, Olsson CA, Bagiella E, Pfaff C, Newhouse JH, Petrylak DP 2000 Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 163:834-837
27. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, Fukui T, Ono Y, Inoue H, Shin M, Tsujimoto Y, Takayama H, Aozasa K, Okuyama A 2001 Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 93:1739-1746
28. Saika T, Kusaka N, Tsushima T, Yamato T, Ohashi T, Suyama B, Arata R, Nasu Y, Kumon H 2001 Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Int J Urol 8:290-294
29. Miller GM, Hinman F 1954 Cortisone treatment in advanced carcinoma of the prostate. J Urol 72:485-496
30. Hamdy FC, Williams JL 1995 Use of dexamethasone for ureteric obstruction in advanced prostate cancer: percutaneous nephrostomies can be avoided. Br J Urol 75:782-785
31. Nishiyama T, Terunuma M 1998 Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer. Int J Urol 5:44-47
32. Smets LA, Salomons G, van den Berg J 1999 Glucocorticoid induced apoptosis in leukemia. Adv Exp Med Biol 457:607-614
33. Distelhorst CW 2002 Recent insights into the mechanism of glucocorticosteroid induced apoptosis. Cell Death Differ 9:6-19
34. Dondi D, Maggi R, Scaccianoce E, Martini L, Motta M, Poletti A 2001 Expression and role of functional glucocorticoid receptors in the human androgen-independent prostate cancer cell line, DU145. J Mol Endocrinol 26: 185-191
35. Koutsilieris M, Grondin F, Lehoux JG 1992 The expression of mRNA for glucocorticoid receptor gene and functional glucocorticoid receptor detected in PA-III rat prostate adenocarcinoma cells. Cancer Res 12:899-904
36. Carollo M, Parente L, D'Alessandro N 1998 Dexamethasone-induced cytotoxic activity and drug resistance effects in androgen-independent prostate tumor PC-3 cells are mediated by lipocortin 1. Oncol Res 10:245-254
37. Smith RG, Syms AJ, Norris JS 1985 Mechanism of the glucocorticoid regulation of growth of the androgen-sensitive prostate-derived R3327H-G8-A1 tumor cell line. J Biol Chem 260:12454-12463
38. Reyes-Moreno C, Frenette G, Boulanger J, Lavergne E, Govindan MV, Koutsilieris M 1995 Mediation of glucocorticoid receptor function by transforming growth factor βI expression in PC-3 prostate cancer cell. Prostate 26:260-269
39. Chang CY, Walther PJ, McDonnell DP 2001 Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res 61:8712-8717
40. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D 2000 Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6: 703-706
41. Mohler JL, Chen Y, Hamil K, Hall SH, Cidlowski JA, Wilson EM, French FS, Sar M 1996 Androgen and glucocorticoid receptors in the stromal and epithelium of prostatic hyperplasia and carcinoma. Clin Cancer Res 2:889-895
42. Berns EM, de Boer W, Mulder E 1986 Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate 9:247-259
43. Gaddipati JP, McLeod DG, Sesterhenn IA, Hussussian CJ, Tong YA, Seth P, Dracopoli NC, Moul JW, Srivastava S 1997 Mutations of the p16 gene product are rare in prostate cancer. Prostate 30:188-194
44. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP 1995 Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398
45. Mc Donald S, Brive L, Agus DB, Scher HI, Ely KR 2000 Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res 60:2317-2322
46. Veldscholte J, Voorhorst-Ogink MM, Bolt-de Vries J, Van Rooij HCG, Trapman J, Mulder E 1990 Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim Biophys Acta 1052:187-194
47. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E 1990 A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-540
48. Culig Z, Stober J, Gast A, Peterziel H, Hobisch H, Radmayr C, Hittmair A, Bartsch G, Cato AC, Klocker H 1996 Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivates of testosterone. Cancer Detect Prev 20:68-75
49. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CYF, Morris JC 2001 In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 8:1524-1531